• Maximize 340B Program Results

    RxStrategies prides itself on offering intuitive contract pharmacy management through advanced reporting and analytics. Our conservative approach to 340B maximizes program results by ensuring more of the 340B savings remain with Covered Entity (CE) through a simple, all-inclusive fee. Another way our contract pharmacy solution is able to maximize results is through our audit-proven eligibility… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Clinical Insights: October 10, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval TegsediTM (inotersen) – October 5, 2018 – Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Intuitive Contract Pharmacy Management through Advanced Reporting and Analytics

    RxStrategies emphasizes a conservative approach to 340B contract pharmacy administration while maximizing program results. Our simple, all-inclusive fee ensures more of the 340B savings remain with the Covered Entity (CE). In addition, our audit-proven eligibility matching algorithm drives matches to qualify each individual transaction. Our 340B Contract Pharmacy Solution: Intuitive, Cloud-Based Platform: Provides unprecedented insights into… Read more »

  • Let’s Connect at the 2018 NACHC CHI & EXPO!

    In just a couple weeks, RxStrategies’ Rhodie Smith and Justin Rolling will attend the National Association of Community Health Centers’ 2018 Community Health Institute (CHI) & EXPO! Taking place August 24-28, 2018 in Orlando, FL, this gathering is the largest of its kind, offering opportunities for health center clinicians, executives, consumer board members and other… Read more »

  • Clinical Insights: August 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are… Read more »

  • 340B Insider – July 2018

    Welcome to the July edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   UPDATES FROM THE 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders during the 340B Coalition Summer Conference in Washington D.C. In addition to being a… Read more »

  • Clinical Insights: July 19, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration… Read more »

  • June 2018 – 340B Insider

                    Welcome to the June edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B INDUSTRY NEWS Read below for recent news from 340B Health. HELP Committee Hearing Update: Support for 340B Hospitals and Other Providers Continues Members of… Read more »